The influence of dexmedetomidine on opioid consumption in radical prostatectomy

KSENJA OGRIČ, NEVA POŽAR-LUKANOVIČ, MATEJ JENKO, MAJA ŠOŠTARIČ, ALENKA SPINDLER-VESEL
Department of Anaesthesiology and Surgical Intensive Therapy, University Medical Centre Ljubljana, Ljubljana, Slovenia

Corresponding author:
Alenka Spindler-Vesel
Department of Anaesthesiology and Surgical Intensive Therapy
University Medical Centre Ljubljana
Zaloška 7, Ljubljana, Slovenia
E-mail: alenka.spindler@guest.arnes.si

ABSTRACT

Objective. Multimodal analgesia and analgesics with different modes of action can reduce perioperative opioid demand and their undesirable side effects.

In our study we presumed that patients anesthetised with additional perioperative dexmedetomidine infusion, during radical prostatectomy, would need less opioids during and after surgery compared to the control group.

Materials and methods. 40 patients, 18-80 years of age, ASA class 1-3 (American Society of Anesthesiologists), scheduled for radical prostatectomy, were included in the study. Patients were randomly divided into two groups (20 pts in each group). In both groups, fentanyl in repeated boluses was used as an analgesic; in the studied group, an additional infusion of dexmedetomidine (0.3 µg/kg/h) was started with intravenous line insertion and continued until the beginning of wound closure. Analgesic consumption during the operation, in the post-anesthesia care unit, in the Intensive Care Unit on the day of the operation and on the first postoperative day was recorded.

Results. The patients with perioperative dexmedetomidine infusion were slightly younger (p=0.007), also the duration of their surgery was shorter (p=0.05). Differences in opioid consumption between the groups were not found. Also, pain assessment, by visual analogue scale (VAS) after 12, 18, 24, 30, 36 and 42 hours, was not statistically different between groups.

Conclusion. In our study, perioperative dexmedetomidine did not reduce peri- and postoperative opioid consumption. Also, undesirable dexmedetomidine side effects, such as bradycardia and hypotension, were not observed.

Key words: dexmedetomidine, radical prostatectomy

INTRODUCTION

Radical prostatectomy is one of the extensive urological procedures associated with strong postoperative pain and a hormonal and metabolic stress response, which can lead to cardiovascular complications, increased occurrence of postoperative paralytic ileus, weakening of the immune response, and changes in carbohydrate and protein metabolism. (1) Optimal perioperative pain management is therefore necessary to inhibit injury triggered pain transfer and reduce the autonomous and somatic pain response. (2)

For postoperative analgesia, an epidural catheter can be used. If there are contraindications or if an epidural catheter cannot be inserted, continuous intravenous infusion of piratramide (patient controlled analgesia, PCA) can be used. (3,4) Epidural analgesia reduces the endocrine and metabolic stress response, facilitates early gut mobility, decreases wound infections and postoperative respiratory complications. (3,5-9)

Given that epidural catheter insertion is an invasive method associated with complications, and that prostatic cancer patients are older, often with comorbidites, degenerative spine changes and on anticoagulants, this method is often avoided. (10) Only opioid based pain relief is associated with adverse reactions (insufficient breathing, nausea, vomiting, constipation, ileus, drowsiness); also, acute tolerance to opioids may develop intraoperatively. (11-13) Multimodal analgesia is the most appropriate method for postoperative pain relief after radical prostatectomy. Pain relief is more effective and opioid side effects are minimized. (2) Combination of opioids, nonopioid analgesics and analgesics with a different mode of action, dexmedetomidine, reduce opioid consumption and their side effects during and after surgery. (14-21)

Dexmedetomidine binds onto a2 adrenergic receptors in the locus ceruleus and posterior horns of the spinal cord. It also inhibits the transfer of pain stimulus and reduces the release of norepinephrine. It acts simpaticotically and therefore reduces mean arterial pressure and heart rate. It also works as an analgesic, hypnotic and anxiolytic drug, and does not inhibit respiratory rate. It also works as an analgesic, hypnotic and anxiolytic drug, and does not inhibit

MATERIALS AND METHODS

Subjects

This prospective study included 40 patients, aged 18 to 80 years, classified according to the American Society of Anesthesiologists (ASA) into groups 1-3, scheduled for radical prostatectomy.

Prior to the operation, patients gave their signed consent for participation in the study and for anaesthesia and surgery. The study protocol was approved by the Medical Ethics Committee of the Republic of Slovenia, at the Ministry of Health of the Republic of Slovenia (KME 54/07/15).

Patients with allergies to a2 agonists, uncontrolled arterial hypertension, the presence of a 2nd or 3rd degree AV block and...
4. Postoperative period

At the end of the operation all patients received paracetamol (1 g) and an intravenous infusion of piritramide with PCA (piritramide 0.5 mg/ml, infusion rate 0.5 mg/h, bolus dose 2 mg, lock out time 30 minutes). If, in the recovery room or in the intensive care unit VAS was ≥ 3, patients first received a bolus dose of piritramide from PCA and then, if necessary, an additional bolus of piritramide (3 mg) and paracetamol (1 g). Consumption of opioids, other analgesics and VAS was evaluated on the day of surgery and on the 1st postoperative day. VAS was recorded also on the 2nd postoperative day.

Statistical analysis

Our first aim was to investigate the differences in general characteristics between groups with use of dexmedetomidine and without use of dexmedetomidine. Mean and standard deviation were used for description.

Student’s t-test was used to compare variables with normal distribution (body weight and body height) while Mann-Whitney U test was used to compare variables that were not normally distributed (age, surgery duration, opioid consumption and other analgesic consumption). Test of normality was made for each observed variable. Secondly, we investigated the influence of dexmedetomidine infusion, piritramide and paracetamol consumption, surgery duration, intraoperative fentanyl use, body weight and body height, age, patient ASA physical status on VAS after 12h with univariate linear regression model. Finally, we evaluated the influence of dexmedetomidine infusion and postoperative piritramide consumption on VAS (visual analogue scale) in first 42h, measured every 6 hours. Complete information provided by the longitudinal data was taken into account estimating mixed-effects regression models, calculated by Medplot. (25)

Medplot is an application for dynamic summary and analysis of longitudinal medical data. The application uses linear regression models for the analysis of numerical outcomes and logistic regression models for binary outcomes; a separate model is fitted for each outcome. The repeated measurements for each subject are taken into account using mixed-effects regression models.

P value of 0.050 was considered statistically significant. Values were corrected for multiple comparison based on the Holm-Bonferroni adjustment. Power of the study (effect size) was calculated post hoc. For statistical analysis Medplot, IBM SPSS Statistics 21 (NY, USA) and Gpower (Kiel, Germany) were used.

RESULTS

Forty patients randomized into two independent groups were included in the study. In Table 1, ASA health status is presented. There was no statistically significant difference in ASA health status among the two groups (Fisher exact probability test, p = 0.303, test value 2.390). Patients’ characteristics and group comparison are shown in Table 2. Patients in the test group with intraoperative dexmedetomidine infusion were on average 6 years younger (p=0.007, Mann-Whitney U test, test statistic 102,50), surgery duration was 16 minutes shorter (p=0.050, Mann-Whitney U test, test statistic 120,6). There was no difference in opioid consumption among groups.

PAIN ASSESSMENT

Pain assessment (VAS) in the postoperative period is shown in Figure 1. Variates used in comparison, and their influence on VAS after 12 hours, are shown in Table 3. Pain assessment after 12 hours was lower in the dexmedetomidine group (linear regression model, p = 0.042. See statistical analysis for details.). VAS values in the postoperative period (12, 18, 24, 30, 36, 42 hours after surgery) were analysed in a mixed regression model for longitudinal comparison. There was no difference among groups in general VAS assessment in 42 postoperative hours (OR 1.19 95%CI 0.29-4.87, p=0.809). Higher piritramide consumption in recovery was related to higher VAS values in the postoperative period, with a Beta coefficient of 1.39 (95% CI 1.08 -1.780, p=0.009).

Figure 1. Pain assessment, shown as VAS score, in first 42 hours after surgery. Average and 95% confidence interval are shown. VAS, visual analogue scale.
Table 1. ASA health status of included patients.

<table>
<thead>
<tr>
<th>Number of patients</th>
<th>Without use of dexmedetomidine</th>
<th>With intraoperative use of dexmedetomidine</th>
<th>total</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASA 1</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>ASA 2</td>
<td>12</td>
<td>16</td>
<td>28</td>
</tr>
<tr>
<td>ASA 3</td>
<td>7</td>
<td>4</td>
<td>11</td>
</tr>
<tr>
<td>total</td>
<td>20</td>
<td>20</td>
<td>40</td>
</tr>
</tbody>
</table>

ASA, American Society of Anaesthesiologists.

Table 2. Patients’ characteristics.

<table>
<thead>
<tr>
<th>Variable</th>
<th>mean (standard deviation) without Dexmedetomidine</th>
<th>mean (standard deviation) Dexmedetomidine group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>69.2 (+7.03)*</td>
<td>63 (+7.54)*</td>
</tr>
<tr>
<td>Body weight (kg)</td>
<td>84.6 (+6.66)</td>
<td>83.2 (+15.1)</td>
</tr>
<tr>
<td>Body height (cm)</td>
<td>174.5 (+5.64)</td>
<td>173.0 (+5.84)</td>
</tr>
<tr>
<td>Intraoperative fentanyl consumption (mg)</td>
<td>0.48 (+0.08)</td>
<td>0.48 (+0.09)</td>
</tr>
<tr>
<td>Surgery duration time (minutes)</td>
<td>157 (+28)**</td>
<td>141 (+31)**</td>
</tr>
<tr>
<td>Piritramide consumption in recovery (mg)</td>
<td>3.37 (+3.27)</td>
<td>2.70 (+2.67)</td>
</tr>
<tr>
<td>Paracetamol consumption (g)</td>
<td>1.68 (+0.82)</td>
<td>1.90 (+1.21)</td>
</tr>
<tr>
<td>Total piritramide consumption (mg)</td>
<td>31.18 (+13.55)</td>
<td>36.87 (+15.93)</td>
</tr>
</tbody>
</table>

*p = 0.007 (statistically significant p value)  
**p = 0.050

Table 3. Influence of variables on VAS after 12 hours (univariate linear regression, see statistical analysis section for details).

<table>
<thead>
<tr>
<th>Variable</th>
<th>Regression coefficient</th>
<th>95%CI</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Piritramide consumption</td>
<td>0.006</td>
<td>-0.043</td>
<td>0.055</td>
</tr>
<tr>
<td>Paracetamol consumption</td>
<td>0.753</td>
<td>-0.105</td>
<td>1.611</td>
</tr>
<tr>
<td>Surgery duration</td>
<td>-0.009</td>
<td>-0.035</td>
<td>0.016</td>
</tr>
<tr>
<td>Intraoperative fentanyl consumption</td>
<td>0.010</td>
<td>-8.985</td>
<td>9.006</td>
</tr>
<tr>
<td>Patient body weight</td>
<td>-0.011</td>
<td>-0.069</td>
<td>0.047</td>
</tr>
<tr>
<td>ASA health status</td>
<td>0.190</td>
<td>-1.259</td>
<td>1.640</td>
</tr>
<tr>
<td>Patient age</td>
<td>-0.052</td>
<td>-0.144</td>
<td>0.040</td>
</tr>
<tr>
<td>Patient body height</td>
<td>-0.050</td>
<td>-0.183</td>
<td>0.083</td>
</tr>
<tr>
<td>Piritramide consumption in recovery</td>
<td>0.102</td>
<td>-0.124</td>
<td>0.328</td>
</tr>
<tr>
<td>Intraoperative use of dexmedetomidine</td>
<td>-1.538</td>
<td>-3.024</td>
<td>0.52</td>
</tr>
</tbody>
</table>

* statistically significant p value  
ASA, American Society of Anaesthesiologists; VAS, visual analogue scale.

POWER OF THE STUDY

Power of the study was evaluated post hoc. Overall piritramide consumption was used in the model simulation. For simulation, Gaussian distribution of parameter was assumed. Significance of 0.05 and power of 0.8 were predicted. Calculated effect size was d=0.90. Difference among dexmedetomidine and test groups in piritramide consumption would be statistically significant if average consumption would differ for 12mg or more.

DISCUSSION

Forty patients, scheduled for radical prostatectomy, were involved in our clinical randomized prospective study. They were randomised into two groups, depending on the type of analgesia received during the operation. Intraoperatively, both groups received fentanyl in repeated doses. In the studied group dexmedetomidine infusion was started after insertion of the intravenous line and stopped at the beginning of wound closure. At the time of study completion, we found out that in the dexmedetomidine group patients were younger and operation time was shorter. Otherwise, there were no differences between the two groups in terms of body height, body weight and ASA physical status. During the operation, fentanyl consumption was recorded, and after surgery, piritramide consumption was noted. We did not find any difference between the groups. So far, few studies have been published which monitor intraoperative opioid
consumption during simultaneous dexmedetomidine infusion. As in our study, Morgan and colleagues did not find any differences in intraoperative opioid consumption during simultaneous dexmedetomidine infusion (initial bolus 1 µg/kg, followed by an infusion of 0.5µg/kg/h). (26) Also, Dong Jian Ge did not notice reduced intraoperative opioid consumption during simultaneous dexmedetomidine infusion (0.4 µg/kg/h). (27)

In contrast, reduced intraoperative opioid consumption during simultaneous dexmedetomidine use has been found in both laparoscopic and classical bariatric surgery and also in laparoscopic and classical hysterectomy. (18,21,28,29) In bariatric operations, Gurbert and Bakhames used a single dose of dexmedetomidine (1 µg/kg or 0.8 µg/kg) for induction in anaesthesia, followed by intravenous infusion till the end of the operation (0.5 µg/kg/h, or 0.4 µg/kg/h). (18)

In laparoscopic and classical gynaecological operations, MC Queen-Shadfar did not find any significant correlation between the dose of dexmedetomidine and intraoperative and postoperative opioid consumption. (28) The same was proven by Tufanogullari, who used different doses of dexmedetomidine, from 0.2 µg/kg up to 0.8 µg/kg. In the same study he demonstrated a correlation between the dose of dexmedetomidine and adverse effects of dexmedetomidine on the cardiovascular system, such as hypotension, hypertension and bradycardia. He, therefore, recommended the smallest dose of dexmedetomidine 0.2 µg/kg/h in order to avoid adverse effects. (22)

In our study, we did not use the initial single dose of dexmedetomidine. There are different opinions regarding this topic. Some recommend it, because it probably prolongs dexmedetomidine analgesic effect postoperatively. (18,20) With an initial dexmedetomidine bolus, efficient dexmedetomidine plasma concentration can be achieved at the beginning of the operation. Others avoid a bolus of dexmedetomidine because of possible side effects. (22,28) Ramsay believes that the use of the initial bolus will depend on the length of anaesthesia. (30) An analgesic effect of dexmedetomidine was proven in healthy volunteers. (31) Feld and Hofer successfully used it in bariatric surgery instead of intraoperative opioids. (20,32) In healthy volunteers, a bolus of dexmedetomidine had a moderate analgesic effect, in comparison to fentanyl, and was found to be most effective at a dose of 0.5 µg/kg/h. (33)

In many studies, the influence of intraoperative dexmedetomidine infusion on postoperative opioid and nonopioid analgesic consumption has been proven. (18, 22, 26, 27, 29, 30, 34-38) Gurbert and Arain found better postoperative analgesia and 66% lower opioid consumption in the first 48 hours after major abdominal surgery. In both studies patients received a single dose of dexmedetomidine (1 µg/kg) at induction of anaesthesia, continued with intraoperative dexmedetomidine infusion (0.5 µg/kg/h). (18, 21, 38) Some authors believe that the extended analgesic effect of dexmedetomidine, which lasts 24 to 48 hours after surgery, is a result of dexmedetomidine half time, which is 2 to 3 hours. Others are of the opinion that its extended analgesia is due to the anxiolytic and thymoleptic properties of α2-agonists, which act on an emotional component of postoperative pain. (18)

Tufanogullari showed that intraoperative dexmedetomidine significantly reduces postoperative opioid consumption and that it does not depend on the dose of dexmedetomidine. (22) It is still not proven whether a bolus dose of dexmedetomidine prolongs postoperative analgesia. (28) Bakhames described decreased opioid consumption on the first postoperative day in patients, who received an induction bolus dose of dexmedetomidine (0.8 µg/kg/h), continued by intraoperative infusion (0.4 µg/kg/h). (21) MC Queen – Shadfar demonstrated reduced postoperative opioid consumption only in the recovery room after classic, but not after laparoscopic hysterectomy, as well. During the operation they used a dexmedetomidine infusion (0.2 - 1 µg/kg/h), without the bolus dose. She concluded that after discharge from recovery, opioid consumption in the first 24 hours after surgery was not decreased. (28) Patients operated laparoscopically, needed equal doses of opioids as those after classical surgery. (39)

Patients who received an intraoperative dexmedetomidine infusion, needed a first bolus of opioid 4 to 6 hours later than patients from the placebo group, which took the first dose of analgesic in the first hours after surgery. (26,36)

In our study, we demonstrated a lower consumption of opioids during and after surgery in a group of patients who received an intraoperative dexmedetomine infusion. The cause could be the fact that these patients were younger than those in the control group. There is evidence that age affects the need for analgesics and sedatives. (40) But in an analysis of the impact of individual factors on VAS after 12 hours, we were not able to find the impact of age and duration of the operations on the intensity of pain. Biovariability also affects pain. Results could be different if all procedures were to be performed by the same surgeon.

In our study, VAS 12 hours after surgery in the dexmedetomidine group was statistically significantly different from the control group. The effect was not detected in the follow up; it was also too small to significantly change the entire load of pain in the postoperative period. With a larger number of patients in our study or a higher-dose of intraoperative dexmedetomidine in the studied group, we might have demonstrated the impact of dexmedetomidine on opioid consumption throughout the whole postoperative period. Similarly, some studies showed that intraoperative use of dexmedetomidine did not affect the assessment of pain, using VAS, despite the fact that decreased postoperative opioid consumption was demonstrated. (22,28,38)

CONCLUSIONS

In our study, we demonstrated that intraoperative use of dexmedetomidine reduces opioid consumption 12 hours after surgery. We might be able to reduce opioid consumption even during and after surgery, if we included a larger number of patients, more homogeneous groups, an initial bolus dose of dexmedetomidine and/or higher intraoperative dexmedetomidine maintenance dose. Side effects of dexmedetomidine, such as hypotension and bradycardia, were not observed in our study.
REFERENCES